RecruitingPhase 1

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

United States392 participantsStarted 2025-12-10

Plain-language summary

To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Be 18+ years old and legally able to consent
✓. Have active psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), suitable for bimekizumab treatment
✓. Weigh between 45-100 kg (females) or 50-100 kg (males).
✓. Be biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve or have stopped bDMARDs ≥3 months or 5 half-lives ago

✕. Serious organ system disorders (e.g., heart, liver, kidney, gastrointestinal, neuro)
✕. Severe psychiatric issues or substance abuse in the past year
✕. Recent or chronic infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB)
✕. Other inflammatory diseases (e.g., rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD))
✕. Recent live vaccines (within 8 weeks) or Bacillus Calmette-Guerin (BCG) (within 1 year)
✕. Recent use of glucagon-like peptide-1 (GLP-1) agonists (within 28 weeks)

Steady-state Trough Concentration (Ctrough,ss) at Week 16

Timeframe: Week 16

NCT IDNCT07290036

SponsorUCB Biopharma SRL

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-05-18

UCB Cares